https://klse.i3investor.com/servlets/ptres/58387.jsp

Despite, expected 40% to 50% q-o-q increase expected in next quarter, Harta is still 10% to 15% lag behind its peers. CIMB is of the opinion, it will increase its ASP further in the following quarter after next (or Apr to Jun 2021), though it was assuming a 2% to 4% decline in ASP m-o-m, from Apr 2021, in its modelling.

Acute global glove shortage unlikely to be resolve soon. There is currently a global shortage of 120 billion glove annually, and that shortage would persist for at least over the next two years. In short, Demand > Supply for at least 2 years and ASP remain strong

Pandemic allocation which is sold at a premium to normal orders has been fully taken up till Oct 2021.

<<will75>> You can get the prevailing P/E from i3 above. Anywhere, here is the sample calculation.

Assumption : RM13 closing price as of Jan 25 2021, not RM12+ today or yesterday.

No of shares : 3.428 billion

Q4 2020 PAT : RM116M
Q1 2021 PAT : RM219M
Q2 2021 PAT : RM545M
Q3 2021 PAT : RM1,001M

Cumulative PAT for 4 quarters is RM1,881M, thus EPS is RM1.881B / 3.428B = 0.55, thereby P/E = RM13/0.55 = 23.6, which is quite close to historical average P/E of 27.69.

Here are the estimated conservative PAT in coming quarters assuming ASP plateau from Apr 2021 and ASP hike by 30% against the revenue (instead of 40% to 50% as suggested by Harta) and disregarding additional 5% capacity from Plant No.7 of which commissioning is expected to be completed by or before Mar 2021.

Q4 FY21 >>> Jan 1 - Mar 31 2021 : RM1,600M
Q1 FY22 >>> Apr 1 - Jun 30 2021 : RM1,600M
Q2 FY22 >>> Jul 1 - Sep 30 2021 : RM1,600M
Q3 FY22 >>> Oct 1 - Dec 31 2021 : RM1,600M

Thereby, cumulative last 4 quarters earning, EPS and P/E are as follows :-

Q4 FY21 (Mar 31 2021) is RM3,365M, EPS = RM3.365B / 3.428B = 0.98, thereby P/E = 13.3
Q1 FY22 (Jun 30 2021) is RM4,746M, EPS = 1.38, P/E = 9.4
Q2 FY22 (Sep 30 2021 is RM5,801M, EPS = 1.69, P/E = 7.7
Q3 FY22 (Dec 31 2021) is RM6,400M, EPS = 1.87, P/E = 7.0

So, the P/E will only drop to single digit from Q1 FY22 onwards, and if you are referring to 6 months Forward P/E or FPE, then it is correct to say that it is already single digit.

Demand will outstrip supply for the next 2 to 3 years, and all you have to do is hold for another quarter or two to see positive movement in the share price. And, if you have better alternative, just sell and move on.

------------------------------------------------------------

will75 Finish school or not? PE single digit la!

Harta ASP is laggard, about half or less than half compared to other big manufacturers. Good thing is that they can raise the ASP, probably throughout 2021 though I assume it plateau from Apr 2021, even more conservative compared to JPM which suggest from Jul 2021. If Harta really raise the ASP by 40% or even 50%, the next quarter may see up to RM2B PAT, though I assume only RM1.6B (again very conservative)

JPM assumption of RM1.6B+ PAT for FY22 (or Apr 1 2021 to Mar 31 2022) is really laughable. Trying to mislead uncle and auntie.

<<gohkimhock>> Don't you think that is a good thing? Do you want to confine with Covid for a long long time? Even Covid is reduced by 70% or 80%, it is still high. We used to have a hundred daily cases or a couple hundred, and now we have thousands.

The problem today is even if you have the money, you can't buy enough glove. Many medical establishment resort to non medical grade glove or no glove at all like the case of Japan where 60% of the respondent already ran out of glove and that was back in Dec, can you imagine what it's like today? https://www3.nhk.or.jp/nhkworld/en/news/backstories/1421/

Many people still cannot take vaccine (apart from below Age 18 group which account for more than 20% of the population) and vaccine efficacy needs time to be perfected. Glove demand would be outstripping supply for some time due to heightened hygiene awareness. Our business associate in Indonesia is also working for the State Own Enterprise (or BUMN), and he has this Whatsapp button that reads "SuksesVaksinasi" and I ask him whether he has already vaccinated but he suggested to wait and see as he has diabetes, high-blood pressure and that sort.

It is good that the world leaders are painting a vibrant picture of the vaccination program though knowing deep in their heart that they are clueless if the vaccine can really bring down (not eradicate) the Covid to a manageable level within 2021.

No of shares : 3.428 billion

Q1 2021 PAT : RM219M
Q2 2021 PAT : RM545M
Q3 2021 PAT : RM1,001M
Q4 2021 PAT : RM1,600M (assuming +30% hike-up on previous quarter revenue, though Harta hinted it would be 40% to 50% q-o-q), Jan 01 - Mar 31 2021

Estimated Total Profit for FY2021 is RM3,365M, thus EPS is RM0.98

3 Years Historical P/E Avg (50.83), thus fair price is RM49.81
5 Years Historical P/E Avg (43.58), thus fair price is RM42.71
10 Years Historical P/E Avg (31.62), thus fair price is RM30.99
All time Historical P/E Avg (27.69), thus fair price is RM27.14
All time lowest Historical P/E (14.84), thus fair price is RM14.54

NOTE : The above is projection for FY21 or Apr 1 2020 to Mar 31 2021, not the entire year of 2021.

If for the entire year of 2021, assuming the ASP plateau from Apr onwards (which is more conservative than JPM which estimate from Jul onwards), while disregarding additional capacity coming online from Plant No.7. The projected earnings are as follows :-

Q4 FY21 >>> Jan 1 - Mar 31 2021 : RM1,600M
Q1 FY22 >>> Apr 1 - Jun 30 2021 : RM1,600M
Q2 FY22 >>> Jul 1 - Sep 30 2021 : RM1,600M
Q3 FY22 >>> Oct 1 - Dec 31 2021 : RM1,600M

Estimated Total Profit for Year 2021 (not FY21) is RM6,400M, thus EPS is RM1.87

3 Years Historical P/E Avg (50.83), thus fair price is RM95.05
5 Years Historical P/E Avg (43.58), thus fair price is RM81.50
10 Years Historical P/E Avg (31.62), thus fair price is RM59.13
All time Historical P/E Avg (27.69), thus fair price is RM51.78
All time lowest Historical P/E (14.84), thus fair price is RM27.75

Even Q3 2021 reported RM1b profit, the P/E is around 23 to 24 which is close to the All Time Historical P/E of 27.69. Wait for another quarter (or two lah). It would be irresistible for the big funds. We can only talk BIG but can't do much to move the share price.

Demand will outstrip supply for the next 2 to 3 years, and all you have to do is hold for another quarter or two to see positive movement in the share price. And, if you have better alternative, just sell and move on.

https://www.bloomberg.com/news/articles/2021-01-25/who-warns-on-vaccine-u-n-issues-call-for-equity-virus-update WHO Warns on Vaccine; Germany Sits on ‘Powder Keg’: Virus Update

Vaccine coverage won’t reach a point that would stop transmission of the virus in the foreseeable future, the World Health Organization said. United Nations Secretary-General Antonio Guterres said the world is risking more virus variations by not pushing for vaccines in developing nations.

BAT has been on a downtrend from 2014 at the high of equivalent to RM74 to today RM13. MPI P/E is pretty high already. Go and invest in your high dividend BAT stock and MPI, come back after 6 months and tell us how much your earn.

https://thepalette.com.my/blog/lets-understand-the-5-main-differences-between-mco-and-cmco/#:~:text=MCO%3A%20All%20tourism%2C%20cultural%2C,activities%20are%20still%20not%20allowed. Let’s Understand the 5 Main Differences between MCO and CMCO.

Actually, there is little difference between MCO2.0 and CMCO (which may be termed as CMCO3.0 later as the last was termed as CMCO 2.0 in Oct 2020).

<drkelvin20> I agree with you. GenM is for long term. Don't expect to earn money this year with CMCO following MCO till May (at least). Probably 2022 onwards. Interstate travel restriction will be in place despite CMCO and we were wondering if GenM will open its door or decided to stay closed in anticipation of very low visitor.

Frankly, I went up to Genting early this year (or first week of Jan) and was expecting a crowd since December was pretty hot, reportedly; But to my surprise, it was dead quiet, theme-park/arcade/bowling/snow-world/etc were closed, most restaurants were closed, probably only 10% are in operational. Without foreigners and if our border remained closed, it is going to be difficult for GenM.

The vaccine roll-out schedule is as follows :-

Phase 1 vaccination : Mar - Mid to May >>> Front liners only
Phase 2 vaccination : Mid of May to July >>> High risk group or senior citizen
Phase 3 vaccination : Aug/Sep onwards for general public age 18 years old and above

Target full inoculation by early 2022. Do expect some delay, hiccup here and there, as well as learning curve, while discounting virus mutation or super-strain while take-up rate may not be that rosy.

With the right mindset and anticipation, we would not be so stress-out when things do not fall in place, and again, this is for long-term investment.

Just FYI, JPM estimated RM2.9B PAT in FY21 (which is not far off compared to above RM3.365B), while TA Securities estimated RM3.56M.

But JPM estimated RM1.62B PAT in FY22 (which is completely off the trajectory as compared to above conservative estimation of RM6.4B assuming ASP plateau from Apr 2021 and disregarding additional capacity from Plant No.7), while Maybank estimated RM6B.

So just to let you know where JPM derive its target price and whether their assumption is right or not. Existing customer on fixed volume allocation already booked up to 12 months, and how did JPM come up with RM1.62B, if next quarter alone already seeing RM1.6B, while ASP is still going up (not even plateau, not to mention when it will come down).

NOTE : Hartalega ASP is still around half of that of other manufacturers.

No of shares : 3.428 billion

Q1 2021 PAT : RM219M
Q2 2021 PAT : RM545M
Q3 2021 PAT : RM1,001M
Q4 2021 PAT : RM1,600M (+30% hike-up on previous quarter revenue), Jan 01 - Mar 31 2021

Estimated Total Profit for FY2021 is RM3,365M, thus EPS is RM0.98

3 Years Historical P/E Avg (50.83), thus fair price is RM49.81
5 Years Historical P/E Avg (43.58), thus fair price is RM42.71
10 Years Historical P/E Avg (31.62), thus fair price is RM30.99
All time Historical P/E Avg (27.69), thus fair price is RM27.14

NOTE : The above is projection for FY21 or Apr 1 2020 to Mar 31 2021, not the entire year of 2021.

If for the entire year of 2021, assuming the ASP plateau from Apr onwards (which is more conservative than JPM which estimate from Jul onwards), while disregarding additional capacity coming online from Plant No.7. The projected earnings are as follows :-

Q4 FY21 >>> Jan 1 - Mar 31 2021 : RM1,600M
Q1 FY22 >>> Apr 1 - Jun 30 2021 : RM1,600M
Q2 FY22 >>> Jul 1 - Sep 30 2021 : RM1,600M
Q3 FY22 >>> Oct 1 - Dec 31 2021 : RM1,600M

Estimated Total Profit for Year 2021 (not FY21) is RM6,400M, thus EPS is RM1.87

3 Years Historical P/E Avg (50.83), thus fair price is RM95.05
5 Years Historical P/E Avg (43.58), thus fair price is RM81.50
10 Years Historical P/E Avg (31.62), thus fair price is RM59.13
All time Historical P/E Avg (27.69), thus fair price is RM51.78

Even if discounted at 50% based upon all time historical P/E average of 27.69, it would translate to RM25.89. Let's wait for the big fund to jump-in in due time.

<<swagger855>> Go somewhere else lah. No one ask you to invest in Harta. Your Math is so-out-of-the-world and your risk assessment/appetite is too low. Regardless whether the price drop or go up this week, I'll hold for at least till 2H2021 unless it hit my target price before-hand.

-------------------------------------------------------------------------

swagger855 And u also didnt take the risk into account. Fd has virtually 0 risk . With that much volatility in harta, harta should be paying a lot of div.

<<BALANCE_VIEW>> I think Harta really focus on business and long term plan, not so much of a "show-manship". They are also very late in hiking the ASP, and still honoring the relationship/arrangement with the prominent buyers (clients).

They just conceived the NGC1.5 plan last year (and it was never in their planning) and they already bought the land next to existing NGC in Sepang, while NGC2.0 which was in their original plan will proceed as planned in Banting. Construction and development already underway, and they will also invest in energy efficient system, automation, IR4.0, etc. It should be up and running from 2022. They are really putting the money to work or good ROE.

Topglov is very "stingy". They are very slow in adopting new technology and with so much cash in hand, they are still asking vendor to propose leasing scheme, rental scheme, BOO scheme, etc. They are also quick in hiking the ASP and taking advantage of the pandemic. TSLWC is really a showman.

Business wise, I prefer Harta, though I'm holding more Topglov than Harta. It really depends on the nature of your investment/trade. It's like Public Bank vs Maybank.

Good news is that full lockdown MCO may not be in sight (hopefully), but the bad news is that CMCO will be in place till at least May (if the number did come down to 2 digits) while we thought all could go back to good-old-December time after the MCO2.0. I have postponed my Club Med plan in Feb to late Mar (school holiday) and it seemed that I need to request to postpone again.

There is negligible different between MCO2.0 and CMCO.

With CMCO in-sight till at least May 2021, it is still very bad for Malaysia economy especially hotel, restaurant, tourism, entertainment (including casino), airline, airport, sports/gym, higher learning (colleges/universities), event management, etc. It would be a multi-billion loss. Many businesses cannot hold up that long with the carry-over burden from 2020.

P/S : Hopefully you have your haircut already as barber was previously not allowed under CMCO.

P/P/S : Many already avoided to go out with the seemingly high daily cases despite whatever government called it i.e. MCO2.0, CMCO3.0, etc.

<<swagger855>> Do you know Math or not? FD 1.75% is per annum, so per quarter or 3 months, you get 1.75% divided by 4 = approx. 0.44%.

Let's say the FD rate for 3 months is 1.75%, and again 1.75% is per annum, not per 3 months (though the applicable rate is 1.75% for 3 months).

If you put RM13,000 into FD today, you'll enjoy 1.75% FD rate but for 3 months, you'll only get RM13,000 x 1.75% x 3/12 = RM56.875. This is far less than Harta dividend of 9.65 cents x 1,000 shares = RM96.50.

If you want to equate Harta dividend to per annum, it is at least 3%, as shown in previous posting above.

Of course TG is way more. No one is stopping you from putting your money in Topglove.

https://www.sustainalytics.com/esg-rating/top-glove-corp-bhd/1015968292/

Topglov ESG rating is quite good actually, just 0.1 off to drop from medium to low risk. Presumably this will be reflected in due time with all the corrective measures in place.

With good ESG, cheap gas and easy access to raw material, it will set Malaysia glove maker apart from others. Most of non-Malaysian glove makers are not risk-assessed as yet. Some are having far worse problem such as “child labour, undocumented workers, unpaid salaries, etc".

<<gemfinder>> Thank you for the article to reassuring us that the worker's issue has not affected Topglove performance. An excerpt from your link reads as follows :-

-------------------------------------------------------------------

BARRIER TO GROWTH?

So far, the controversy over worker rights has done little to dim the success of firms such as Top Glove.

Analysts predict growth to continue as long as the coronavirus remains. Even as vaccines are introduced, the average selling price for gloves is likely to continue to climb, they say.

<<swagger855>> The statement above is just to counter your earlier comment suggesting the dividend is less than FD but it is not. Anyway, going by your logic, please put your money in Topglove then.

Harta is my client. I like the management, and how they conduct business, while they enjoy highest historical P/E among all glove makers (just to show the investors confident level in Harta). They already embark into automation, IR4.0, energy efficient system thus most advanced with lowest production cost among all, sending the team to Google campus to import the good working culture, etc.

Good news is that full lockdown MCO may not be in sight (hopefully), but the bad news is that CMCO will be in place till at least May (if the number did come down to 2 digits) while we thought all could go back to good-old-December time after the MCO2.0. There is very little different between MCO2.0 and CMCO, otherwise almost no different.

With CMCO in-sight till at least May 2021, it is still very bad for Malaysia economy especially hotel, restaurant, tourism, entertainment (including casino), airline, airport, sports/gym, higher learning (colleges/universities), etc. Many businesses cannot hold up that long with the carry-over burden from 2020.

P/S : Hopefully you have your haircut already as barber was previously not allowed under CMCO.

9.65 cents out of RM13 closing today is 0.74% x 4 quarters = 2.97% which is much higher than FD, averaging less than 2%.

Though we know for sure the PAT will be even higher next quarter and subsequent quarter for the rest of 2021.

http://www.sustainalytics.com/esg-rating/hartalega-holdings-bhd/1043036811/

Wow! Hartalega ESG is so good (or very low risk). Hopefully, it could attract more funds with the aggressive business plan and expansion till 2027 (with anticipated of 95 billion capacity as opposed to 44 billion by FY22) including the Anti-Microbial Glove technology (AMG).

CMCO till end of May? WTF! Thought we could go back to business after Feb.

Can GenM open or not? Previously, GenM is not allowed to open during CMCO.

<<Steve Ooi>> Good news is that full lockdown MCO may not be in sight (hopefully), but the bad news is that CMCO will be in place till at least May. There is very little different between MCO2.0 and CMCO, otherwise almost no different.

Hopefully you have your haircut already as barber was previously not allowed under CMCO.

With CMCO in-sight till at least May 2021, it is still very bad for Malaysia economy especially hotel, restaurant, tourism, entertainment, airline, airport, sports/gym, higher learning (colleges/universities), etc.

<<bearcomebullgone>> 6.6% still tested positive after taking the Pfizer vaccine in Israel is NO GOOD. In Stage 3 clinical trial, only 8 out of 170 tested positive belongs to participants which had taken 2 doses of Pfizer, out of a pool 41,135 that went through the test. 8 out of 41,135 multiply by 2 (assuming half are given the vaccine and the other half placebo) is 0.04%. So 6.6% is 165 times more than expected.

95% efficacy is derived from 8 people out of 170 tested positive from vaccinated group while 162 from placebo group. 8: 162 or 5% : 95%. Don't be confused.

And, if the precentage of people without vaccine but gotten infected is less than 6.6%, then the vaccine is causing more harm than good in actual, or that it may suggest the vaccine is ineffective against the new variant that we may have known or not known as yet.

<<al8800>> Clear evident EPF intend to hold long term thus lend it out (or SBL) to shorties earning a fee, enjoying dividend at the same time and capital appreciation in longer term. EPF win ALL.

The above is a pretty inofrmative forum on Covid situation, RSS, IBs estimated earning on major glove companies in 2021 through 2023 (though most likely will be revised upward in due time), historical PE, intrinsic value of major glove companies in bearish and bullish case, etc.

Surprisingly, JPM give quite a favorable earning estimation on Topglove in 2021.

In short, even in bearish case in 2023, Top Glove is still undervalue, not to mention the yummiicious 16% to 20% annual dividend.

P/S : The host himself used to work with the IB and give a little insight of the IB and short-selling.

https://www.youtube.com/watch?v=kvZLCpAubRk Glove on or Glove Off?

https://www.cnbc.com/2021/01/21/dr-fauci-says-covid-vaccines-appear-to-be-less-effective-against-some-new-strains.html?recirc=taboolainternal

Some early findings that were published in the preprint server bioRxiv, which have yet to be peer reviewed, indicate that the variant identified in South Africa, known as 501Y.V2, can evade the antibodies provided by some coronavirus treatments and may reduce the efficacy of the current line of available vaccines.

-------------------------------------------------------------

There is still very little that we know of this Covid-19. It kept mutating. Best is to adhere to SOP.

https://www.cnbc.com/2021/01/22/biden-says-nothing-can-change-the-trajectory-of-covid-pandemic-over-the-next-several-months.html

-----------------------------------------------------------------------

Don't know how whether my company can sustain the operation and its people if the Covid-19 and lockdown persist. Can't keep bleeding for long ............

https://www.cnbc.com/2021/01/21/dr-fauci-says-covid-vaccines-appear-to-be-less-effective-against-some-new-strains.html?recirc=taboolainternal Dr. Fauci says new data shows Covid vaccines appear to be less effective against some new strains

Some early findings that were published in the preprint server bioRxiv, which have yet to be peer reviewed, indicate that the variant identified in South Africa, known as 501Y.V2, can evade the antibodies provided by some coronavirus treatments and may reduce the efficacy of the current line of available vaccines.

-------------------------------------------------------------

There is still very little that we know of this Covid-19. It kept mutating. Best is to adhere to SOP.

Biden plan will put more money to Testing and PPE i.e. Testing (US$50 billion) > PPE (US$30 billion) > Vaccination (US$20 billion).

Biden plan will put more money to Testing and PPE i.e. Testing (US$50 billion) > PPE (US$30 billion) > Vaccination (US$20 billion).

https://www.statnews.com/2021/01/14/biden-request-covid-19-response/ Biden requests $415 billion from Congress to ramp up the country’s Covid-19 response

The massive plan, outlined in an address Thursday evening, would allocate $20 billion for a national vaccination program; ***** $30 billion for purchasing supplies and protective gear *****; and $50 billion for a scaled-up diagnostic testing program. It would represent the federal government’s biggest investment yet in public health efforts to address the pandemic; the December stimulus package, for example, put just $9 billion toward vaccine distribution, $20 billion toward vaccine procurement, $3 billion toward the Strategic National Stockpile and $22 billion toward testing and tracing efforts.

-------------------------------------------------------

Upcoming US$30 billion for purchasing supplies and protective gear compared to a meagre US$3 billion toward Strategic National Stockpile in Dec 2020. It seemed that more money will be going to Testing (US$50 billion) > PPE (US$30 billion) > Vaccination (US$20 billion).

https://www.statnews.com/2021/01/14/biden-request-covid-19-response/ Biden requests $415 billion from Congress to ramp up the country’s Covid-19 response

The massive plan, outlined in an address Thursday evening, would allocate $20 billion for a national vaccination program; ***** $30 billion for purchasing supplies and protective gear *****; and $50 billion for a scaled-up diagnostic testing program. It would represent the federal government’s biggest investment yet in public health efforts to address the pandemic; the December stimulus package, for example, put just $9 billion toward vaccine distribution, $20 billion toward vaccine procurement, $3 billion toward the Strategic National Stockpile and $22 billion toward testing and tracing efforts.

-------------------------------------------------------

Upcoming US$30 billion for purchasing supplies and protective gear compared to a meagre US$3 billion toward Strategic National Stockpile in Dec 2020. It seemed that more money will be going to Testing (US$50 billion) > PPE (US$30 billion) > Vaccination (US$20 billion).

TSLWC should initiate more share buyback and then enlisted in HKEX at the earliest (without additional share issuance). Single digit P/E in next QR (or Mar 2021) would be very attractive while TopGlov production is about 5 times bigger than Intco but Intco is market cap is CNY90B or around RM56B which is more than TG today at around RM52B.

------------------------------------------------------------

BloomBird Intco Medical Technology Co Ltd
SHE: 300677
286.88 CNY +32.53 (12.79%)
22 Jan, 2:21 pm GMT+8 · Disclaimer

Upcoming US$30B for purchasing supplies and protective gear will dwarf the Dec stimulus contributing US$3B toward the Strategic National Stockpile.

Upcoming US$30B for purchasing supplies and protective gear will dwarf the Dec stimulus contributing US$3B toward the Strategic National Stockpile.

Upcoming US$30B for purchasing supplies and protective gear will dwarf the Dec stimulus contributing US$3B toward the Strategic National Stockpile.

The massive plan, outlined in an address Thursday evening, would allocate $20 billion for a national vaccination program; ***** $30 billion for purchasing supplies and protective gear *****; and $50 billion for a scaled-up diagnostic testing program. It would represent the federal government’s biggest investment yet in public health efforts to address the pandemic; the December stimulus package, for example, put just $9 billion toward vaccine distribution, $20 billion toward vaccine procurement, $3 billion toward the Strategic National Stockpile and $22 billion toward testing and tracing efforts.

----------------------------------------------------

https://www.statnews.com/2021/01/14/biden-request-covid-19-response/ Biden requests $415 billion from Congress to ramp up the country’s Covid-19 response

https://www.statnews.com/2021/01/14/biden-request-covid-19-response/ Biden requests $415 billion from Congress to ramp up the country’s Covid-19 response

The massive plan, outlined in an address Thursday evening, would allocate $20 billion for a national vaccination program; ***** $30 billion for purchasing supplies and protective gear *****; and $50 billion for a scaled-up diagnostic testing program. It would represent the federal government’s biggest investment yet in public health efforts to address the pandemic; the December stimulus package, for example, put just $9 billion toward vaccine distribution, $20 billion toward vaccine procurement, $3 billion toward the Strategic National Stockpile and $22 billion toward testing and tracing efforts.

https://www.statnews.com/2021/01/14/biden-request-covid-19-response/ Biden requests $415 billion from Congress to ramp up the country’s Covid-19 response

The massive plan, outlined in an address Thursday evening, would allocate $20 billion for a national vaccination program; ***** $30 billion for purchasing supplies and protective gear *****; and $50 billion for a scaled-up diagnostic testing program. It would represent the federal government’s biggest investment yet in public health efforts to address the pandemic; the December stimulus package, for example, put just $9 billion toward vaccine distribution, $20 billion toward vaccine procurement, $3 billion toward the Strategic National Stockpile and $22 billion toward testing and tracing efforts.

Intco is going up and reaching all time high. With less than 19billion gloves production (or around 20% of TG) but reaches 86billion market cap. TG should expedite the listing in HKEX.

<sea2sea> Malaysia 642 death out of 172,549 which translate to less than 0.4% death and more than 99.6% recovered. Even without vaccine the number is much much better.

Please note that many countries are in some form of lockdown and that has been extended to Feb and Mar.

Anyway, let's wait and see and hopefully the vaccine works to some degree but it will not eradicate Covid for now till the scientist has a better understanding of Covid-19.

--------------------------------------------------------------

sea2sea Look at the cases, 99.6% in mild condition. Only 0.4% in serious/critical.

97% recovered, 3% dead.

https://www.worldometers.info/coronavirus/

Daily cases around the world 8s dropping since vaccine is out.

This is the fact. Graph lie?

<<Aurora13>> 6.6% still tested positive after taking the Pfizer vaccine in Israel is no good. In Stage 3 clinical trial, only 6 out of 170 tested positive belongs to participants which had taken 2 doses of Pfizer, out of a pool 41,135 that went through the test. 6 out of 41,135 multiply by 2 (assuming half are given the vaccine and the other half placebo) is 0.03%. So 6.6% is 220 times more than expected.

And, if the precentage of people without vaccine but gotten infected is less than 6.6%, then the vaccine is causing more harm than good in actual, or that it may suggest the vaccine is ineffective against the new variant that we may have known or not known as yet.

<<Primeinvestor> In terms of volume TopGlove is still the largest and Malaysia command about 60% of the world market supply. Hartalega is the largest nitrile glove supplier in the world.

Market cap is a different altogether like Tesla is the biggest by market cap but production volume and sales revenue is far far behind all the major automakers.

1.2% RSS x 8.2B Shares x RM6 (just an assumption) = around RM590M? Maybe TG Owner (with his huge dividend payout) can buy-in.

Assuming DSLWC holds 2.8B Shares @ RM0.165 dividend = RM462 Million per quarter and expected to get even higher payout in next quarter due to additional 20% dividend and significantly higher PAT i.e. no less than RM3B (compared to approx. RM2.4B PAT last quarter).

Biden latest US$1.9T aid are mostly extending till end of Sep 2021 including US$50B toward Covid-19 testing. JPM just shot itself in the foot by suggesting the number of testing is dwindling. https://covidtracking.com/data/charts/us-daily-tests

---------------------------------------------------------------------

https://www.cnbc.com/2021/01/14/biden-stimulus-package-details-checks-unemployment-minimum-wage.html Biden’s $1.9 trillion Covid relief plan calls for stimulus checks, unemployment support and more

https://www.cnbc.com/2021/01/14/biden-stimulus-package-details-checks-unemployment-minimum-wage.html

Biden’s $1.9 trillion Covid relief plan calls for stimulus checks, unemployment support and more

$50 billion toward Covid-19 testing

- The aid are mostly extending till end of Sep 2021 including US$50B toward Covid-19 testing. JPM just shot itself in the foot by suggesting the number of testing is dwindling.

https://covidtracking.com/data/charts/us-daily-tests

https://www.cnbc.com/2021/01/14/biden-stimulus-package-details-checks-unemployment-minimum-wage.html

Biden’s $1.9 trillion Covid relief plan calls for stimulus checks, unemployment support and more

$50 billion toward Covid-19 testing

- The aid are mostly extending till end of Sep 2021 including US$50B toward Covid-19 testing. JPM just shot itself in the foot by suggesting the number of testing is dwindling.

https://covidtracking.com/data/charts/us-daily-tests

Moderna CEO says the world will have to live with Covid ‘forever’ at JPMorgan Health Conference